

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Health Technology Evaluation**

**Equality impact assessment – Scoping**

**Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes, it was noted during consultation that is important to consider the population of people with Lennox-Gastaut seizures living in long term care and/or those with Lennox-Gastaut seizures associated cognitive impairment and/or learning disability and ensure that there are no barriers to access to the available treatments. It was also noted that this target population is likely to have intellectual disabilities and may have difficulty communicating adverse effects and therefore this should be carefully monitored by carers and medical attendants.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This issue will be taken into account in the committee’s decision making.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No

**Approved by Associate Director (name):** ...Linda Landells

**Date:** 31 May 2023